IHS Chemical Week

World News and Views :: Projects

Lonza to Expand Cytotoxic API Capacity in Switzerland

12:48 AM MDT | May 12, 2011 | Deepti Ramesh

Lonza says it will invest SF24 million ($27 million) to expand cytotoxic manufacturing capabilities at the company’s site at Visp, Switzerland. Cytotoxic active pharmaceutical ingredients (APIs) are widely used in oncology therapeutics, one of the fastest growing segments of the pharma and biotech industries, Lonza says. “This investment speeds our efforts to establish the Lonza Visp site as a center of excellence for high potency manufacturing,” says Stefan Stoffel, head of Lonza’s chemical manufacturing business unit. “With the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa